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Multiple sclerosis (MS) is a chronic disease of the central nervous system responsible for a large portion of neurological
disabilities in young adults. Similar to what occurs in numerous complex diseases, both unknown environmental
factors and genetic predisposition are required to generate MS. We ascertained a set of 63 Finnish MS families,
originating from a high-risk region of the country, to identify a susceptibility gene within the previously established
3.4-Mb region on 17q24. Initial single nucleotide polymorphism (SNP)-based association implicated PRKCA (protein
kinase C alpha) gene, and this association was replicated in an independent set of 148 Finnish MS families (p¼0.0004;
remaining significant after correction for multiple testing). Further, a dense set of 211 SNPs evenly covering the PRKCA
gene and the flanking regions was selected from the dbSNP database and analyzed in two large, independent MS
cohorts: in 211 Finnish and 554 Canadian MS families. A multipoint SNP analysis indicated linkage to PRKCA and its
telomeric flanking region in both populations, and SNP haplotype and genotype combination analyses revealed an
allelic variant of PRKCA, which covers the region between introns 3 and 8, to be over-represented in Finnish MS cases
(odds ratio¼1.34, 95% confidence interval 1.07–1.68). A second allelic variant, covering the same region of the PRKCA
gene, showed somewhat stronger evidence for association in the Canadian families (odds ratio¼1.64, 95% confidence
interval 1.39–1.94). Initial functional relevance for disease predisposition was suggested by the expression analysis:
The transcript levels of PRKCA showed correlation with the copy number of the Finnish and Canadian ‘‘risk’’ haplotypes
in CD4-negative mononuclear cells of five Finnish multiplex families and in lymphoblast cell lines of 11 Centre d’Etude
du Polymorphisme Humain (CEPH) individuals of European origin.
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Introduction
Multiple sclerosis (MS) is a chronic disease of the central
nervous system responsible for a large portion of neuro-
logical disabilities in young adults. Similar to what occurs in
numerous complex diseases, twin, adoption, and epidemio-
logical studies indicate a complex etiology in which both
unknown environmental factors and genetic predisposition
are required to generate the disease [1–3]. Genome scans
have revealed several putative susceptibility loci [4–7]. In
addition to the human leukocyte antigen (HLA) locus on
6p, loci on 5p, 17q, and 19q have been replicated in
multiple study samples [8–11]. Further, a recent high-
density linkage screen utilizing 4,500 SNPs in 730 multiplex
MS families of Northern European descent implicated the
chromosome 17q as a locus with the second most signiﬁcant
maximum logarithm of odds (MLS) score (2.45) after the
HLA [12].
The prevalence of MS in Finland is 50–100/10
5, similar to
other populations of Northern European descent living in a
temperate climate [13]. However, in the Southern Ostro-
bothnian health-care district of Seina ¨joki, located on the
western coast of Finland, distinctly higher incidence (12/
10
5) and prevalence (200/10
5) rates have been established
[14,15]. This regional subisolate also shows exceptional
familial clustering of MS [16]. Our genome-wide analyses
have identiﬁed four main loci in Finnish MS families: the
HLA class II region, the MBP locus on 18q, and two linked
regions on 5p12-p14 and 17q22-q24 [7,17–19]. The rela-
tively wide 17q locus, syntenic to rat experimental allergic
encephalomyelitis (Eae) locus on rat chromosome 10 [20]
was further restricted by haplotype analysis in Finnish
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containing fewer than 20 transcripts [21]. The chromosomal
architecture surrounding this critical MS locus was found
to be complex, the area being ﬂanked by large duplicated
segments and areas enriched with palindromic sequence
stretches, which are present also in the chimp genome [22].
Interestingly, the critical MS region is inverted in the
chimp and human with respect to the order in the mouse
genome.
To identify MS-associated allelic variants in Finnish
families within this critical DNA region, we ﬁrst constructed
a sparse map of 67 SNP markers spanning the 3.4-Mb
interval, and genotyped these SNPs in our primary material
consisting of 22 multiplex and 41 trio families originating
from the high-risk region. The same set of families was used
in our previous ﬁne-mapping study to deﬁne the critical
DNA region on 17q [21]. The initial analysis revealed four
SNPs of the PRKCA gene to show some evidence for
association with MS [23]. To explore this gene and the
ﬂanking regions in more detail and to potentially identify
speciﬁc allelic variant(s) predisposing to MS, we next
constructed a denser panel of 211 SNPs covering and
ﬂanking the PRKCA gene, and genotyped them in two large,
independent MS cohorts from Canada and Finland. The
initial single SNP association was replicated in the second set
of 148 Finnish families and an SNP haplotype analysis
identiﬁed allelic variants of PRKCA, which were over-
represented in Finnish (n ¼ 211) and Canadian (n ¼ 554)
MS cases. Our initial association with PRKCA gene was also
quickly reproduced in the United Kingdom case-control
study [24]. This makes PRKCA a strong candidate for the gene
underlying the linkage and association observed at this locus
in several populations. Taking into account the critical role
of the PRKCA and associated cellular pathways in regulating
immune response, it may also be involved in other auto-
immune diseases.
Results
Stage I: Preliminary Screen for SNP-Based Association on
17q24
Sixty-seven SNPs mapping to 53.7–65.0 Mb on 17q24,
covering and ﬂanking the critical 3.4-Mb MS region (Figure
1), were genotyped in a set of 22 multiplex and 41 trio
families from the high-risk region containing a total of 327
individuals, including 97 MS cases (Table 1, Study set I). This
regionally ascertained study sample should minimize the
genetic and environmental heterogeneity. Forty of the 67
selected SNPs mapped within the 3.4-Mb DNA region
translating to an average 85-kb inter-SNP interval. Nine
SNPs showed some evidence for association to MS (p , 0.05)
in transmission disequilibrium test (TDT) or haplotype-based
haplotype relative risk (HHRR) analyses [25]. Strongest
evidence for association was observed with a SNP rs7220007
(p¼0.002), which maps to the PRKCA gene. Three other SNPs
of PRKCA also showed nominal evidence for association
(rs759118, p¼0.02; rs741141, p¼0.01; and rs887797, p¼0.02).
The minor allele frequencies and the results of TDT and
HHRR analyses for all 67 SNPs are given in Table S1.
Stage II: Replication of the Association in an Independent
Set of 148 Finnish MS Families
To capture most of the genetic variation of the PRKCA
gene implicated as a primary positional candidate by the
initial SNP-based analysis, and to potentially identify allelic
variant(s) predisposing to MS, 211 SNPs mapping to the
PRKCA gene and the 1-Mb ﬂanking regions (see Materials and
Methods for details) were selected from the dbSNP database
(http://www.ncbi.nlm.nih.gov/projects/SNP) to evenly cover
the region, and genotyped using a BeadArray platform in
211 Finnish MS families (Table 1, Study sets I þ II). This
provided a dense SNP map with an average 12-kb spacing
between SNPs throughout the region, and an average inter-
SNP distance of 8 kb within the PRKCA gene. Thirteen of the
selected 211 SNPs had already been genotyped in 184 Finnish
MS families originating from the high-risk region (as
described for Stage I), and served here as controls between
the different SNP genotyping platforms. We observed zero to
one discrepancies for each SNP in the genotypes between the
different genotyping platforms, making the discrepancy rate
  0.15%.
A total of 148 of the 211 Finnish MS families (Table 1, Study
set II) genotyped using the dense SNP set were independent
from those utilized in stage I and were used here to replicate
the initial SNP results. These families also originated from the
high-risk regional subisolate, with a restricted number of
Table 1. Description of the Study Material
Study Set Description Families Individuals MS Cases
Study set I MS Finland (primary set),
multiplex and nuclear
63 327 97
Study set II MS Finland, nuclear 148 720 151
Study set III MS Canada, multiplex
and nuclear
554 2,729 1,584
All Finnish MS families originated from a regional high-risk subisolate.
DOI: 10.1371/journal.pgen.0020042.t001
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Synopsis
Complex diseases such as multiple sclerosis (MS) likely result from
problems in networks of interactions between several genes and
largely unidentified environmental and lifestyle factors. Identifica-
tion of MS-specific genes has been challenging. HLA-DRB1*15 is the
only consistent locus observed in most populations; however, the
recent genome scan on more than 700 European families implicated
17q as a second-best MS locus [12]. Since MS families from the high-
risk region of Finland initially revealed linkage to 17q, the authors
used the regionally ascertained set of 63 families to identify a MS
predisposing gene within a major non–HLA locus on 17q. The initial
association was observed with single nucleotide polymorphisms
(SNPs) located in intron 3 of the PRKCA (protein kinase C alpha) gene
in Finnish MS families and replicated in an independent set of 148
MS families from Finland and 554 from Canada, two populations
with a different genetic background. Combining the data of two
SNP variants revealed two allele combinations of PRKCA, which were
over-represented in Finnish or Canadian MS cases (odds ratio¼1.34,
95% confidence interval, 1.07–1.68, and odds ratio ¼ 1.64, 95%
confidence interval 1.39–1.94, respectively). Linkage and association
of the PRKCA gene, encoding a regulator of immune responses, in
two populations imply its involvement in the etiology of MS.founders. Four of the 178 high-quality SNPs with minor allele
frequency   5% showed evidence for association in the
HHRR analysis (p , 0.01) in this independent set of 148
Finnish MS families. The strongest evidence was observed
with SNP rs887797 (p ¼ 0.0004, the experiment-wide
signiﬁcance threshold to keep the type I error rate at 5%
was 0.0005, thus the association remains signiﬁcant after
conservative correction for multiple testing), located in
intron 3 of the PRKCA gene and implicated in the initial
SNP analysis. The three other SNPs showing suggestive
association were rs987931 (p ¼ 0.009), rs1318 (p ¼ 0.005),
and rs2365403 (p ¼ 0.003) (Figure 1 and Table 2). The HHRR
results p , 0.05 are shown in Table 2, and the results for all
211 SNPs are given in Table S2. Table 2 also shows the HHRR
results for the combined Finnish dataset (Study sets I þ II).
Association observed in the Finnish study sample seemed to
be independent of the HLA, at least in this pre-selected set of
families originating from a geographical high-risk region for
MS (unpublished data).
Stage III: Testing the Association of PRKCA Gene in a More
Heterogeneous Canadian Population
To evaluate the relevance of the association observed in
two independent sets of Finnish MS families in a more
heterogeneous population, the same set of 211 SNPs was
genotyped in 554 Canadian MS families (Table 1, Study set
III) using a BeadArray platform. A total of 165 of the 211 SNP
provided good quality data and had the minor allele
frequency   5% in the Canadian sample (Table 2). Although
the SNP showing strongest evidence for association in Finnish
families, rs887797, failed to reveal association in Canadian
families, two SNPs next to rs887797, located less than 28 kb
apart, provided suggestive evidence for association in the 554
Canadian families (rs2078153, p ¼ 0.0097, and rs1860984, p ¼
0.0099), the latter being also suggestively associated in the 148
Finnish families (p ¼ 0.019) (Table 2). Two other SNPs with p
, 0.01 in the Canadian MS sample were rs4790896 (p ¼
0.0038) and rs2363846 (p ¼ 0.0046). The HHRR results p ,
0.05 are shown in Table 2, and the results for all SNPs are
given in Table S2.
To monitor for potential difference in background allele
frequencies between two populations, we selected the ten
most centromeric SNPs (rs724560–rs4630583, see Table S2),
which did not show evidence for association to MS and were
not in linkage disequilibrium (LD) with the SNPs of the
PRKCA gene, and performed comparisons between Finns and
Canadians using Genepop (Genepop on the Web [http://
wbiomed.curtin.edu.au/genepop], option 3: population differ-
entiation). A difference was observed in the distribution of
genotypes between the Finnish and Canadian families (p ¼
0.026). Thus, the ﬁnding of different SNPs showing the
strongest evidence for association in these two Caucasian
populations is not totally surprising.
Multipoint Linkage Analysis
The non-parametric linkage analysis option of MERLIN,
which can accommodate marker-marker LD, was used to test
for linkage in the Finnish and Canadian MS families [26].
Figure 1. Schematic Representation of the MS Locus on Chromosome 17q24
Positions of the SNPs used in stages I, II, and III are shown with arrowheads. Grey arrowheads indicate SNPs showing evidence for association: stage I, p
, 0.05; stage II, p , 0.01. SNP rs887797 showing evidence for association in the two independent Finnish study sets (Study sets I and II) is shown with a
black arrow. The horizontal bar indicates the position of the critical MS region identified by haplotype analysis in our previous study [21]. The positions
of the genes mapping to the locus are shown as boxes below.
DOI: 10.1371/journal.pgen.0020042.g001
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region were selected for the multipoint analysis (for details
see Materials and Methods). Two of the 12 SNPs (rs887797
and rs2078153) had pairwise r
2 above the selected threshold
and were combined in the analysis. Although the information
content of SNPs is lower than that of microsatellite markers, a
maximum non-parametric linkage score of 2.33 in the
combined dataset suggested evidence for linkage to the
PRKCA region in both populations.
LD Blocks and Haplotype Analyses of the PRKCA Locus
To facilitate the analyses of allelic haplotypes, the level of
LD within the PRKCA gene was evaluated using the Haplo-
view program, version 3.2 [27]. We observed nine distinct
haplotype blocks within the PRKCA gene, the size of which
varied between 1 and 107 kb (Figure 2). Haplotype blocks 1–3
were identical in Finns and Canadians, but there were some
differences in the block boundaries within blocks 4–9. The
SNPs in blocks 4–9 show substantial LD with each other and
with the SNPs in the 107-kb interval deﬁned by block 3. The
SNPs providing strongest evidence for association in the
PRKCA gene in Finnish and Canadian MS families (rs887797
and rs2078153, respectively) are located in the haplotype
block 4.
Because of the LD observed between SNPs located in blocks
3–9 (Figure 2), we decided to test also SNPs outside the block
4 in the haplotype analysis. Association was calculated for
seven SNP haplotypes constructed from SNPs rs4561502,
rs2319523, rs2048716, rs2361486, rs741141, rs887797,
rs2361491, rs1010546, and rs1010544 (the positions of the
SNPs are indicated in Figure 2) in 211 Finnish MS families
using the TDT-based Haploview 3.2 custom association test
option (results for all tested haplotypes are shown in Table
S3) [27]. The C-A allele of the two-SNP haplotype (rs887797–
rs1010544) was over-transmitted (corrected p¼0.039) and the
T-A allele under-transmitted (corrected p ¼ 0.031) to the MS
cases of Finnish families. The same haplotype (rs887797–
rs1010544) was also tested in the Canadian MS families, but
no association was observed (p . 0.1). To test if there would
be evidence for another predisposing allele in the Canadian
population, we used SNP rs2078153, which shows the
strongest evidence for association in Canadian families, and
a second SNP, rs3890137, located in block 7, which is
suggestively associated in Canadians, in the haplotype analysis
(the positions of the SNPs are indicated in Figure 2); and
observed the G-A allele to be under-transmitted (corrected p
¼ 0.035) to MS patients in the Canadian families.
To extract all available information from the complete
family sets, we also used genotype combinations of two SNPs
(rs887797 and rs1010544 in Finns; rs2078153 and rs3890137
in Canadians) to monitor for potential allele frequency
differences between the MS cases and the family controls,
since only 30% of the Finnish and 32% of the Canadian MS
families had both parents available, which is a requirement
for a TDT-based analysis. The genotypes of one MS case (one
random case from multiplex families) and one random
Table 2. HHRR Association Results for the Dense Set of SNP (p-Values , 0.05) in Finnish and Canadian MS Families
Gene SNP
a Location
b Study Set II Study Sets I þ II
c Study Set III LD between SNPs
d
p-Value
e p-Value
e p-Value
e
MGC33887 rs987931 64316013 0.009 0.054 n/a D9 ¼ 1.0
rs2287243 64427807 0.041 0.035 0.852 m
rs4791083 64719896 0.059 0.077 0.035 j
PRKCA rs2048716 65074094 0.110 0.015 0.397 j
rs2361486 65085980 0.081 0.012 0.095 j
rs741141 65097755 0.071 0.013 0.104 j
rs2078153 65101916 0.062 0.016 0.010 j D9 ¼ 0.69 D9 ¼ 1.0 D9 ¼ 0.22
rs1860984 65104438 0.019 0.241 0.010 .m m m
rs887797 65129546 0.0004 0.0001 0.256 jjj
rs2361491 65153675 0.012 0.003 0.387 jjj
rs1010546 65234666 0.084 0.008 0.916 jjj
rs759117 65251724 0.151 0.046 0.515 jjj
rs3889477 65273551 0.266 0.213 0.023 jjj
rs3803821 65287818 0.222 0.040 0.176 jjj
rs3803819 65336046 0.138 0.016 0.671 jjj
rs733646 65376150 0.123 0.038 0.930 jjj
CACNG4 rs4790896 65526675 0.856 0.179 0.004 . jj
rs11193 65616980 0.390 0.128 0.018 jj
HELZ rs763333 65637409 0.048 0.020 n/a jj
rs973225 65684969 0.035 0.029 0.155 jj
rs2363846 65696930 0.048 0.020 0.005 . j
PITPNC1 rs2949942 66048921 0.511 0.640 0.042 j
rs1318 66241483 0.005 0.002 0.405 .
rs2365403 66246200 0.003 0.002 0.525
aSNPs located within a gene indicated in the first column are shown in red.
bLocation on Chromosome 17 according to UCSC Genome Browser, July 2003 freeze.
cResults in the combined Finnish dataset (Study sets I þ II).
dLD between SNP pairs was calculated using the Haploview program, version 1.1.
eValues in boldface are p , 0.2.
n/a, not applicable.
DOI: 10.1371/journal.pgen.0020042.t002
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PRKCA Associated with Multiple SclerosisFigure 2. Haplotype Block Structure of the PRKCA Gene in Finnish and Canadian Populations
(A) shows the block structures of the PRKCA gene (between SNPs rs3764402 and rs4791037) in 211 Finnish MS families; (B), in the 554 Canadian MS
families. The haplotype blocks were created using the solid line of LD of the Haploview program, version 3.2 [27]. The SNPs providing strongest
evidence for association to MS in PRKCA in Finns and Canadians (rs887797, rs2361491 and rs2078153, rs1860984, respectively) are marked with black
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PRKCA Associated with Multiple Sclerosishealthy control from each family were used to calculate
frequencies of observed allelic combinations of two-SNPs.
The genotype combination analysis provided further evi-
dence for these alleles deﬁned by two-SNP haplotypes: The
genotype combination (rs887797 and rs1010544) C-A was
more frequent in Finnish MS cases compared to healthy
controls from the same families (frequency: 0.58 in cases, 0.51
in controls, odds ratio [OR] ¼ 1.34, 95% conﬁdence interval
[CI]: 1.07–1.68), whereas an allele combination T-A was
under-represented in Finnish MS cases (Table 3). In the
Canadian families, a genotype (rs2078153–rs3890137) combi-
nation C-A was over-represented in Canadian MS cases
(frequency: 0.23 in cases, 0.15 in family controls, OR ¼ 1.64,
95% CI, 1.39–1.94), whereas combination G-A was under-
represented (Table 4).
As another indication of the complexity of this genome
region, we also saw putative evidence for association with the
SNPs mapping telomeric to the PITPNC1 gene in Finns, and
these SNPs, unlike the suggestively associated SNPs in CACNG
and HELZ genes, were not in high LD with the best PRKCA
SNPs (see Table 2). To address potential involvement of this
genome region, the Haploview 3.2 haplotype analysis was
calculated for the two SNPs (rs2625563–rs1318), showing
putative evidence for association as single SNPs in Finns, in
Finnish and Canadian MS families. The two SNPs were in full
LD and provided a p-value of 0.003 in Finnish families, but no
evidence for association was observed in the Canadian
families (p . 0.5).
Sequencing of the Coding Regions of the PRKCA Gene
To exclude structural alterations in the PRKCA protein as a
potential cause for MS, we sequenced the coding regions
(including 30–50 bases of exon–intron boundaries) and 1.700
bases of the promoter of the PRKCA gene in ten unrelated
Finnish MS patients, of which ﬁve had at least one copy of the
putative disease allele (rs887797–rs1010544: C-A). We also
sequenced the coding regions in eight healthy population
controls. We found one polymorphic (GCC)-repeat located in
the promoter region and 12 SNPs (Table 5). Three of the
SNPs were located in the promoter region, two of them novel,
whereas the other nine were either in exons or in exon–
intron junctions (for details, see Table 5). SNP rs1010546,
which showed nominal evidence for association in Finnish MS
families, was located 11 bases from the junction of the exon 7
and in a sequence conserved between the mammalian species.
However, we obtained no evidence of alternative splicing in
blood mononuclear cell RNAs of four individuals (two cases
and two controls), carrying the two different genotypes for
this SNP (CC and CT).
One of the novel SNPs, located in the exon 15, changes a
codon of amino acid valine (GTC) to isoleucine (ATC), which
seems to represent the ancestral amino acid in this position,
the codon for isoleucine being conserved in the other species
( c h i m p ,m o u s e ,r a t ,d o g ,c h i c k e n ,f u g u ,a n dz e b r a ﬁ s h ) .
Although, the current human consensus sequence shows the
allele G in this position, all sequenced healthy controls and
ﬁve of the seven MS patients had an AA genotype in this
position, whereas two MS patients had one or two copies of
the G allele. These MS cases carried two and zero ‘‘risk’’
alleles of PRKCA, respectively. Further, we genotyped this G/A
polymorphism in 30 Finnish nuclear MS families (96
individuals) and found the G allele to be rare (frequency
0.05) in the Finnish population: It was seen only in three of
the 30 families. All individuals carrying the rare G-allele had
at least one copy of the putative ‘‘risk’’ allele, but considering
the low frequency of the G allele, this coding region variant
cannot solely explain the association observed with the ‘‘risk’’
allele.
Tissue and Cellular Expression of PRKCA
To be relevant for the molecular pathogenesis of MS, a
gene would be expected to be expressed either in tissues
relevant for immune response, such as thymus or blood
leukocytes, or in tissues affected by the disease process.
Malfunctioning T lymphocytes or antigen-presenting cells
could have a role in causing the disease. We studied the
expression of the PRKCA gene by using the Human Fetal
MTC and Human Immune System MTC cDNA panels
(Clontech, Palo Alto, California, United States), and found
it to be expressed in the relevant immunological tissues, like
thymus, lymph node, and pool of blood leukocytes, as well as
in a target tissue, the brain (unpublished data). RT-PCR
revealed PRKCA mRNA to be expressed by antigen-present-
ing dendritic cells, by CD4
þ T lymphocytes, and in a cell pool
containing CD4
  blood mononuclear cells (Figure 3A).
We also monitored for the potential difference in the
expression level of the PRKCA gene in the freshly collected
peripheral blood mononuclear cells using quantitative real
time RT-PCR. The cells were stratiﬁed to two cell populations
according to the presence or absence of the CD4 surface
antigen. The relative level of the PRKCA expression was
measured in cells of MS cases and healthy members of ﬁve
multiplex MS families (total of 20 samples). We compared the
transcript levels in individuals with two or one ‘‘risk’’ alleles
of PRKCA and observed an interesting difference: There was
a 2-fold difference in the expression of PRKCA in CD4
  cells
between individuals carrying one copy of the putative risk
allele (n ¼ 7) versus individuals who had two copies of the
same allele (n¼9) (cycle threshold [Ct]¼25.9 6 0.65 standard
deviation [SD] and 26.9 6 0.58 [SD], respectively), the
expression being lower in individuals with two copies of the
putative disease allele, disregarding the disease status (Figure
3B). The difference was somewhat larger in affected
individuals (Ct ¼ 25.5 6 0.39 [SD] in heterozygotes and 27.0
6 0.27 [SD] in homozygotes), which translates to 3-fold less
PRKCA transcript in MS patients with two copies of the
putative risk allele. This data suggests a regulatory element
controlling the PRKCA expression segregating with the ‘‘risk’’
haplotype. Such a difference was not seen in CD4
þ cells (0.7-
fold difference, n ¼3 þ 7, respectively). Samples from
individuals without the putative risk allele were not available
for the expression studies.
Due to non-accessibility of CD4-selected lymphocytes of
Canadian patients, we addressed the role of the Canadian
‘‘risk’’ allele in the regulation of the PRKCA gene by using the
publicly available expression and genotype data of Centre
d’Etude du Polymorphisme Humain (CEPH) individuals from
two recent publications by Monks and collaborators [28] and
Hinds and co-workers [29]. Monks et al. [28] measured the
arrows, SNPs used in Haploview version 3.2 [27] haplotype analysis in 211 Finnish families are indicated with boxes, and those used in the two SNP
genotype combinations are indicated with a white arrowhead with the letter H and the rs-numbers given above.
DOI: 10.1371/journal.pgen.0020042.g002
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PRKCA Associated with Multiple Sclerosisexpression of 23,499 genes in lymphoblastoid cell lines for
members of 15 CEPH families. Hinds et al. characterized
whole-genome patterns of human DNA variation by genotyp-
ing over 1.5 million SNPs in 71 CEPH individuals [29]. Eleven
European-American CEPH individuals were utilized in both
studies, and these samples had both expression and genotype
data available for the PRKCA gene. We estimated the SNP
haplotypes for the CEPH individuals of European ancestry
using the Phase program (for details, see Materials and
Methods) and found that one CEPH individual had two copies
of the putative risk haplotype (rs2078153–3890137: C-A), one
had one copy, and nine had no copies. Interestingly, similarly
as observed for Finnish samples, the relative expression level
of PRKCA was lower in the individual having two copies of
the ‘‘risk’’ haplotype compared to individuals with one or no
copies of that haplotype (0.004 versus 0.108).
Other Potential Genes within PRKCA
Although the SNPs with the strongest association to MS are
located in intron 3 of PRKCA, the analysis showed consid-
erable inter-marker LD between most of the SNPs located in
a DNA region covered by intron 3 through intron 8, making
this more than 200-kb interval the most probable position for
the disease susceptibility variant. According to the UCSC
Human Genome Browser (May 2004 assembly; http://www.ge-
nome.ucsc.edu), there are two variant forms of PRKCA:
mRNA variant AB209475 includes an additional exon in the
intron 3, and the other variant, BC053321, two exons in the
intron 8 (Figure 3C). The ﬁrst variant form was observed in a
brain library, but there are no EST (expressed sequence tag)
clones corresponding to the variant exon 3b. The second
variant mRNA was identiﬁed in an epidermoid carcinoma
library, and an EST clone BM020079 containing the same
sequences existed in an astrocytoma library. Further, there
are three other mRNAs with unknown function mapping to
this interval: AF194537, AK098118, and AK130736. We also
made an effort to identify all the EST clones mapping to the
critical interval using the UCSC Human Genome Browser
(Figure 3C). We could identify over 120 non-overlapping EST
clones within this DNA region, over 70 within intron 3.
Discussion
Complex diseases such as MS most probably result from
problems in networks of interactions between several genes
and as yet unidentiﬁed environmental and lifestyle factors.
Even though studies in MS families have identiﬁed a limited
number of linked loci, replicated in several populations,
identiﬁcation of MS genes or DNA variants speciﬁc to MS has
been a challenging task, and several initial ﬁndings showing
association, especially to candidate genes, have failed to be
replicated in other populations. Only association of MS with
HLA-DRB1*15 has been conﬁrmed in most studies (reviewed
in [30]), yet the role of this locus in MS susceptibility has
remained unknown. Here we aimed to identify an MS gene
and disease-associated allelic variants at the 17q locus for
which we have established linkage and initial evidence for a
restricted chromosomal region among individuals with MS in
Finnish families originating from a high-risk subisolate of
Finland [21]. A recent high-density SNP linkage scan
indicated this locus as a locus with the second highest MLS
score in a large collection of families of Northern European
descent [12]. Initial evidence for association with SNPs
mapping to intron 3 of the PRKCA gene was established in
the same Finnish study samples providing evidence for
linkage. This association with PRKCA was replicated in the
second set of 148 MS nuclear families collected from the
high-risk region. Considering the historical and demographic
differences between Finns and Canadians, as well as the
difference in the background allele frequencies between
these two populations, it was not surprising that the MS-
associated allelic haplotypes were deﬁned by different sets of
SNPs. A comparable difference was observed for SNPs within
the HLA region between these same sets of MS families:
Different SNP blocks within the HLA class II region showed
strongest association to MS in Finnish and Canadian families
[19]. However, both the Finnish (rs887797–rs1010544: C-A)
and the Canadian (rs2078153–rs3890137: C-A) risk haplotype
covers the same region of the PRCKA gene: a DNA segment
from intron 3 through intron 8. The observed ORs for both
populations are in good agreement with the ks value of 1.18
estimated for this locus by the International Multiple
Sclerosis Consortium linkage screen [12].
A recent study in the UK population [24] replicated our
initial ﬁnding of the PRKCA association [23]. A total of 35
SNPs mapping to PRKCA were genotyped in 184 unrelated MS
cases and 340 controls collected from the UK. Three SNPs
showing putative evidence for association (best p-value ¼
0.0018) were located in the 39 end of PRKCA, whereas the two
associated two-SNP haplotypes covered the ﬁrst two exons
Table 3. Two-SNP (rs887797 and rs1010544) Genotype Combi-
nations in Finnish MS Families
Genotype
Combinations
Finnish MS Cases
a Finnish Parent/Sib
b OR 95% CI
n ¼ 604 Frequency n ¼ 612 Frequency
CA 351 0.58 311 0.51 1.34 1.07–1.68
TA 113 0.19 151 0.25 0.70 0.53–0.92
CG 115 0.19 117 0.19
TG 25 0.04 33 0.05
aOne MS case was randomly selected from each family; 151 cases had genotype for both
SNPs.
bOne healthy control/family was randomly selected from the same families; 153 had
genotypes for both SNPs.
DOI: 10.1371/journal.pgen.0020042.t003
Table 4. Two-SNP (rs2078153–rs3890137) Genotype Combina-
tions in the Canadian MS Families
Genotype
Combinations
Canadian Cases
a Canadian Controls
b OR 95% CI
n ¼ 2,216Frequencyn ¼ 1,636Frequency
CA 512 0.23 253 0.15 1.641.39–1.94
GA 1,046 0.47 843 0.52 0.840.74–0.95
GG 388 0.18 383 0.23
CG 270 0.12 157 0.10
aOne MS case was randomly selected from each family; 554 cases had genotype for both
SNPs.
bOne healthy control/family was randomly selected from the same families; 409 had
genotypes for both SNPs.
DOI: 10.1371/journal.pgen.0020042.t004
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intron and exon of PRKCA (PRKCA*30_31), thus ﬂanking the
genetic region showing association in Finns and Canadians.
In addition to the PRKCA gene, we observed some evidence
for association to MS with individual SNPs located in CACNG/
HELZ genes in Canadian MS families and telomeric to the
PITPNC1 gene in Finnish MS families. This can be explained
by LD between the best PRKCA SNPs and the SNPs in CACNG/
HELZ genes. However, no LD was found between the critical
PRKCA SNPs and the PITPNC1 SNPs, thus this feature cannot
explain the observed association on this region. The Canadian
study sample did not show any association with PITPNC1 SNPs
(rs1318 and rs2365403), which tempers the interest to this
region. However, considering the complex structure of this
chromosomal region, the more complex association pattern
on 17q could also indicate that the SNPs in the broader region
showing association to MS are in linkage disequilibrium with
an as yet unidentiﬁed duplication, inversion, or another
chromosomal rearrangement polymorphism affecting some
or several genes located within this interval. A recent study by
Gonzalez and co-workers [31] observed signiﬁcant interindi-
vidual and interpopulation differences in a copy number of a
segmental duplication encircled gene encoding CCL3L1 and
found that possession of a CCL3L1 copy number lower than
the population average markedly enhanced HIV susceptibil-
ity. Stefansson and co-workers [32] also recently identiﬁed a
common inversion, which is under positive selection in
Europeans and maps to 17q21.31. We have shown that the
critical MS region on 17q24 is ﬂanked by palindromic
segments and highly-homologous duplicated sequences, which
can predispose to large chromosomal rearrangements by
nonallelic homologous recombination [22].
PRKCA is an excellent functional candidate for predis-
position to MS, since the disease is believed to be the result of
misdirected immune response by autoreactive T cells against
myelin antigens [33], and protein kinase C (PKC) plays a
critical role in signal transduction controlling T-lymphocyte
activation. The PRKCA has been functionally implicated in T-
cell receptor/CD28-induced interleukin 2 (IL-2) gene expres-
sion and has also a critical role in regulating IL-2 receptor
expression (reviewed in [34]). IL-2 can initiate cell cycle
progression during T-cell activation. IL-2 signals via the IL-2
receptor and phosphatidylinositol 3-kinase (PI3K), a pathway
mediated downstream by the E2F transcription factor family
[35]. A recent study by Iglesias and co-workers [36] observed
enhanced E2F pathway transcription in peripheral blood
mononuclear cells from MS patients. We can hypothesize that
the enhanced transcription of E2F pathway genes could be a
result of altered PRKCA activity in those patients.
We observed a distinct difference in the relative levels of the
PRKCA expression in CD4
  mononuclear cells between
individuals with one or two copies of the risk haplotype
identiﬁed here, regardless of the disease status. Interestingly,
expression and genotype data available inthe public databases
supported our ﬁndings: The PRKCA expression seemed to
correlate with the copy number of the Canadian risk allele in
lymphoblast cell lines derived from the CEPH individuals of
European ancestry. We acknowledge that the number of
samples is still too small for deﬁnitive conclusions, but further
studies to evaluate whether a variant segregating with the
putative disease haplotype has an effect in the expression of
the PRKCA are warranted. Also, the blood mononuclear cell
pool might not be the optimal cell type to look for the
potential difference in the expression of the PRKCA gene; this
feature should also be assessed in the antigen-presenting cells.
The MBP locus on chromosome 18q is another locus
showing evidence of linkage and association to MS in these
Finnish families [17]. Interestingly, Feng and co-workers [37]
showed that a golli product of the myelin basic protein (MBP)
gene can serve as a negative regulator of signaling pathways
in T lymphocytes, particularly involving the PKC pathway.
The golli product expressed in T lymphocytes, BG21, can be
phosphorylated by PKC, but the inhibition of the PKC
pathway is independent of the phosphorylation. The negative
regulation by BG21 is not due to direct action on PKC
activation, but in the cascade following PKC activation. Thus
these two loci may actually act in concert to confer
susceptibility to MS.
Considering the role of the PRKCA in regulating immune
response of T cells and the fact that this locus on chromosome
17q was found to be one of the human non-HLA autoimmune
clusters sharing conserved genetic location with animal
autoimmune loci [38], it is tempting to speculate that PRKCA
might also have a role in susceptibility to other autoimmune
diseases, especially those mapping to the 17q24 locus, like
rheumatoid arthritis and psoriasis. Barton and co-workers
[39] observed both linkage to the region and association to a
marker D17S807, which is located next to the PRKCA gene, in
rheumatoid arthritis ASP families, when studying human loci
syntenic to two rat models of inﬂammatory arthritis. A
genome-wide scan by Nair and collaborators [40] provided
evidence for a psoriasis susceptibility locus also on this region
of 17q. The PRKCA gene is one of the key components in a
pathway that regulates immune responses, and is located in a
region shown to harbor susceptibility gene(s) for several
human autoimmune diseases and animal autoimmune/inﬂam-
matory disease models. Thus it serves as an excellent
functional and positional candidate for predisposition to
other human and animal autoimmune diseases.
Table 5. Sequencing of the Coding Regions of the PRKCA Gene
Name rs Number Variation Location Function
PRKCA-2 rs3764402 T/C PRKCA promoter
PRKCA-3 Novel T/C PRKCA promoter Potential SIF/Sp1
binding site
PRKCA-4 Novel (GCC)n PRKCA promoter
PRKCA-5 Novel G/A PRKCA promoter Potential Sp1/H4TF2
binding site
PRKCA-6 rs1010546 C/T Exon 7–intron 7
junction
Conserved base at
exon–intron junction
PRKCA-7 Novel C/T
a Intron 7
PRKCA-8 Novel G/A Exon 8 Silent, no amino
acid change
PRKCA-9 rs3803821 T/A
a Intron 11
PRKCA-10 Novel G/C Exon 13 Silent, no amino
acid change
PRKCA-11 Novel C/T Intron 13
PRKCA-12 rs6504459 G/A
a Exon 15 Amino acid change
valine!isoleucine
PRKCA-13 Novel G/A Exon 16 Silent, no amino
acid change
PRKCA-14 rs9898776 G/A Intron 16
aOriginal base according to conservation in other species.
DOI: 10.1371/journal.pgen.0020042.t005
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Finnish MS pedigrees. The primary study material consisted of 22
multiplex MS families with two to six affected cases per pedigree, and
41 MS patients with their parents and/or unaffected sibs, all
originating from the high-risk region for MS in the Southern
Ostrobothnia of Finland (Table 1, Study set I). The families are
identical to those previously described in our ﬁne-mapping study
[21]. In an extension to the primary study sample, 148 nuclear
families (affected family member and her/his parents or, in case of a
missing parent, two to four healthy siblings) have been collected from
the same region in Southern Ostrobothnia (Table 1, Study set II).
There were altogether 63 full trios (MS caseþboth parents) available
in these datasets. All families were Finnish and of Caucasian descent,
Figure 3. Expression of the PRKCA Gene and Overview of the Gene Region
(A) RT-PCR analysis of expression of the PRKCA gene in isolated human cells.
(B) Relative levels of the PRKCA gene expression in CD4
  blood mononuclear cells in individuals with one (n[controls] ¼ 4, n[MS] ¼ 3) or two copies
(n[controls]¼4, n[MS]¼5) of the ‘‘risk’’ MS haplotype. Ct(PRKCA) values are normalized against mean of Ct(HMBS) and Ct(b-actin) and are shown on the
y-axis and the number of putative disease haplotypes (rs887797–rs1010544: C-A) in the x-axis. (Ct¼number of amplification cycles required to reach the
selected signal threshold, thus higher Ct values mean lower relative expression levels). Expression in MS cases is shown with black diamonds and in
healthy controls with white squares (average 6 SD are given for all individuals as horizontal lines).
(C) UCSC Human Genome Browser view of the critical region of the PRKCA gene (chr17:61,980,000–62,158,000). The genomic DNA region covered by
haplotype blocks 4–7 (in Canadians) and blocks 4–9 (in Finns) is indicated on top. The ruler shows map positions on chromosome 17 (UCSC Genome
Browser, April, 2004). Names and positions of the SNPs used in the haplotype analysis are shown above the ruler. The names of the mRNA clones
corresponding to the PRKCA gene variants are shown on the left and to the three other mRNA clones beside them in the middle. The spliced and
unspliced ESTs, respectively, are shown in the middle of the figure. Conservation between species and the repeat masker are indicated below.
DOI: 10.1371/journal.pgen.0020042.g003
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PRKCA Associated with Multiple Sclerosisand at least one of the parents was born in Southern Ostrobothnia.
Diagnosis of MS in affected individuals strictly followed Poser’s
diagnostic criteria [41]. All individuals gave their informed consent,
and the study has been approved by the Ethics Committee for
Ophthalmology, Otorhinolaryngology, Neurology, and Neurosurgery
in the Hospital District of Helsinki and Uusimaa. (Decision 46/2002,
Dnro 192/E9/02).
Canadian MS pedigrees. A cohort of 554 MS families were
ascertained as part of the ongoing Canadian Collaborative Project
on the Genetic Susceptibility to MS (CCPGSMS), for which the
methodology has been described previously [42]. This cohort consists
of families with at least one affected sibling pair (n ¼ 399), families
with affected parent-child pairs (n ¼ 49), simplex (n ¼ 97), and
extended families (n ¼ 21). There were 211 full trios (MS case þ both
parents) available in this dataset. All families were Canadian and of
Caucasian descent.
Genotyping. To control for sample mix-ups, all Finnish samples
were analyzed to determine the gender of the sample and genotypes
of four microsatellite markers using the ABI 3730 (Applied
Biosystems, Foster City, California, United States). The data were
compared to the known sex of the samples and checked for
Mendelian errors. Discrepant samples were excluded from the
analyses.
Stage I: We identiﬁed a set of 135 SNPs mapping to 53.7–65.0 Mb
on 17q24 between markers D17S1290 and D17S789 on chromosome
17, covering and ﬂanking the 3.4-Mb MS region, which showed
evidence for excessive allele sharing and linkage to MS in large
Finnish multiplex families (Figure 1). At the time (1999), a signiﬁcant
proportion of the SNPs in the publicly available database were not
veriﬁed, thus only 67 of 135 SNPs were proven to be polymorphic in
our sample set and passed our quality criteria for large-scale
genotyping. SNPs in stage I were genotyped using the MassARRAY
System (Sequenom, San Diego, California, United States), allele-
speciﬁc primer extension on microarray or Pyrosequencing (Pyrose-
quencing, Uppsala, Sweden). Details for individual SNPs provided
upon request from JS. For the MassARRAY System (Sequenom), we
used 5 ng of DNA/reaction. The SNP assay was designed using
SpectroDESIGNER (Sequenom), and the PCR and extension reac-
tions were done as speciﬁed by the manufacturer. Genotypes were
automatically called with the SpectroCALLER software (Sequenom),
and manually checked as described [43]. Part of the SNPs in stage I
were genotyped in a multiplex using allele-speciﬁc primer extension
on microarrays with a protocol developed in our laboratory and
described by Pastinen and co-workers [44] with minor modiﬁcations.
Two allele-speciﬁc detection oligonucleotides were designed for each
SNP and synthesized (Operon, Alameda, California, United States)
with a 59aminolinker and a poly-T (9T) stretch followed by the SNP-
speciﬁc sequence. The oligonucleotides were spotted in duplicate
onto silane/isothiocyanate-coated chrome mirror microscope slides
(Evaporated Coatings, Willow Grove, Pennsylvania, United States)
using a robot built in-house. Sequences containing the SNPs were
ampliﬁed from genomic DNA in multiplex PCR reactions (up to ﬁve
SNPs together) using SNP-speciﬁc primers with T3 (forward) or T7
(reverse) tails. (Speciﬁc PCR conditions can be obtained from author
JS by request). Multiplex reactions were pooled and in vitro
transcribed using the AmpliScribe T7 or T3 High Yield Trancsription
Kit (Epicentre Technologies, Madison, Wisconsin, United States). The
DNase I–treated T3 or T7 RNA pools were hybridized to the arrays in
a hybridization buffer containing 1.67 M NaCl at 42 8C for 20 min.
Arrays were washed twice in 0.3M NaCl, 0.53TE, 0.1% TritonX-100,
followed by a short rinse in ice-cold water. Subsequently, the allele-
speciﬁc extension was performed using MMLV Reverse Transcriptase
(Epicentre Technologies) in a 20-ll reaction containing 50 mM Tris-
HCl (pH 8.3), 10 mM MgCl2, 75 mM KCl, 10 mM DTT, 0.5 lM dATP,
0.5 lM dGTP, 0.5 lM ddATP, 0.5 lM ddGTP, 1.0 lM FluoroLink Cy5-
dCTP, 1 lM FluoroLink Cy5-dUTP (both Amersham Pharmacia
Biotech, Piscataway, New Jersey, United States), 15% glycerol, and
0.24 M Trehalose, at 50 8C for 20 min. A 59 Cy3-(A)9 39 blocked probe
(Operon) was added to the hybridization reaction to monitor for
efﬁciency in the array production. Finally, arrays were washed twice
in 0.3M NaCl, 0.5 3 TE, 0.1% TritonX-100, followed by a short rinse
in ice-cold water, air dried, and scanned using a GMS418 Array
Scanner (Affymetrix, Santa Clara, California, United States). The
image was analyzed using the Scanalyze software (http//:rana.lbl.gov/
EisenSoftware.htm). Genotypes were clustered and called using a
program developed in-house (W. Wong and C. Li, unpublished data).
The rest of the SNPs analyzed in stage I were genotyped using
Pyrosequencing as speciﬁed by the manufacturer.
Stage II: 211 SNPs mapping to the PRKCA gene and to 1-Mb
centromeric and telomeric ﬂanking regions (chr17: 60.72–63.23 Mb)
were identiﬁed from the dbSNP database and selected to evenly cover
the PRKCA gene and its 1-Mb ﬂanking regions. The SNP selection was
independent of stage I, except that the SNPs (rs759118, rs741141,
rs7220007, and rs887797) showing evidence for association to MS in
stage I were also included here. Selected SNPs were genotyped using
the BeadArray platform (Illumina, San Diego, California, United
States) as described in Fan and co-workers [45]. Thirteen SNPs
already genotyped in stage I were re-genotyped by BeadArray
platform in order to evaluate the accuracy of the genotyping. We
found zero to one discrepancies/676 genotyped individuals for each
SNP between the platforms, making the discrepancy rate less than
0.15%. All SNP genotypes were checked for Mendelian errors. Of the
211 SNPs, 178 and 165 markers had minor allele frequency greater
than 5% and genotype call rate greater than 90% in the Finnish and
Canadian samples, respectively, and were used in the statistical
analyses.
Statistical analyses. SNP genotypes obtained from different
genotyping platforms were coded as follows: A ¼ 1, C ¼ 2, G ¼ 3,
and T¼4. Allele calling depended on the orientation from which the
SNP was genotyped. Allele and genotype frequencies were deter-
mined from the data, and deviation from the Hardy-Weinberg
equilibrium was tested using Pearson’s chi-square test. HHRR and
TDT analyses of the ANALYZE package were used in the primary
analysis (stage I) to monitor for association [25]. TDT and HHRR
utilize only the data of full trios (MS case þ both parents, one trio is
utilized in families with multiple MS cases), but HHRR is able to make
use of families in which both parents are not heterozygotes for a
given marker. Thus HHRR was used in the stage II analysis. We used
the SNPSpD method (http://genepi.qimr.edu.au/general/daleN/
SNPSpD) [46] with modiﬁcations by Li and Ji [47] to correct for
multiple testing. According to SNPSpD, the effective number of
independent SNP loci was 100.1808, thus the experiment-wide
signiﬁcance threshold of 0.0005 was required to keep the type I
error rate at 5%. In the text, all p-values for individual SNPs are
presented as non-corrected.
To test for potential interaction between the HLA locus and the
locus on chromosome 17q24, we stratiﬁed the Finnish MS families
ﬁrst according to the HLA type using SNP rs2239802, which is located
in the HLA region and shows strong evidence for association (p¼33
10
 10 in HHRR) to MS. Families were divided into three subgroups
based on whether the affected individual had two, one, or no copies
of the risk SNP allele (n ¼ 46, n ¼ 76, and n ¼ 48 families/subgroup,
respectively), and association was monitored in each subgroup using
the HHRR.
Genepop Option 3, sub-option 3 (population differentiation:
genotypic differentiation; http://wbiomed.curtin.edu.au/genepop)
was used to compare the background allele frequencies between
Finnish and Canadian MS families. The genotypes of the ten most
centromeric SNPs (Table S2, rs724560–rs4630583) of 265 independ-
ent, healthy Finnish and Canadian individuals were utilized in the
analysis with the default Markov chain parameters. A corrected p-
value is given in the text (df ¼ 20, Fisher’s method).
We used the non-parametric multipoint linkage analysis of
MERLIN (version 0.10.2, http://www.sph.umich.edu/csg/abecasis/
Merlin/index.html) to test for evidence of linkage in the combined
set of Finnish and Canadian families, since it can accommodate LD
between markers [26]. MERLIN’s option rsq q( q ¼0.01),w h i c h
calculates pairwise r
2 between neighboring markers and creates a
cluster joining markers for which pairwise r2 . q and all intervening
markers, was employed. Twelve SNPs were selected for the multipoint
analysis: one SNP from haplotype blocks 1–3 of the PRKCA gene
(rs3764402, rs973752, rs2361486), two strongest associating SNPs
(rs2078153, rs887797) from block 4, rs1985633 from blocks 5–6, and
rs3889477 from block 9 (Finnish)/blocks 7–9 (Canadian). In addition
to the PRKCA SNPs, we included SNPs rs733646 (telomeric to
PRKCA), rs4790896 (CACNG4), rs2363846 (HELZ), rs2949942
(PITPNC1), and rs2365403 (AK094724).
The level of LD between the SNPs was calculated using all
polymorphic SNPs located in PRKCA in Finnish and in Canadian MS
trios with the Haploview program, version 3.2 [27]. The Haploview 3.2
custom association test option was used to monitor for association of
seven haplotypes formed by SNPs rs4561502, rs2319523, rs2048716,
rs2361486, rs741141, rs887797, rs2361491, rs1010546, and rs1010544
(indicated by boxes in Figure 2), which either showed association in
211 Finnish MS families as single SNPs or were located in the same
haplotype block as an associated SNP. The haplotype showing
strongest association in Finns (rs887797–rs1010544) was tested in
Canadian families using the Haploview 3.2. custom test option, as was
a haplotype of SNPs rs2078153 and rs3890137, which showed putative
association as single SNPs or were in the same block as a putatively
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to calculate haplotype association for SNPs rs2625563–rs1318,
covering the DNA region telomeric to the PITPNC1 gene, in Finnish
and Canadian families. p-Values for putative risk/protective hap-
lotypes (rs887797–rs1010544:C-A/T-A in Finnish and rs2078153–
rs3890137:G-A in Canadian MS families) were calculated by compar-
ing one allele to the other three alleles, and the p-values were
corrected for multiple testing using the permutation option available
in Haploview 3.2 (1,000 permutations).
Since only one third of the families had both parents available, we
further used genotype combinations to test for differences between
the MS cases and family controls in the Finnish and Canadian
datasets. One MS case (one randomly selected MS case from multicase
families) and one random control individual were selected from each
family to calculate the observed genotype combinations for SNPs
rs887797 and rs1010544 in Finns and SNPs rs2078153 and rs3890137
in Canadians. ORs were calculated by comparing the putative risk/
protective allele to all the other alleles.
Individual two-SNP haplotypes (rs887797–rs1010544) were as-
signed for members of the multiplex families used in the PRKCA
expression analysis utilizing the sufﬁcient phase information avail-
able in these families.
Sequencing. MS cases of trio families and one MS patient from
multiplex families were randomly selected for sequencing. Anony-
mous Finnish control DNAs were used as reference samples. The
primers were designed by using the on-line primer design software
Primer3 input (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi). All primers had a melting temperature (Tm)
between 58 8C and 60 8C. The segment was ampliﬁed by PCR and
sequenced in both directions using the ABI PRISM 377 DNA
Sequencer (Applied Biosystems) with BigDye terminator chemistry
and standard conditions (Applied Biosystems). The sequence data was
analyzed using ABI Sequencing Analysis 3.3 (Applied Biosystems),
Sequencher 4.0.5 (Gene Codes Corp., Ann Arbor, Michigan, United
States), and the published genome sequence (UCSC Human Genome
Browser, July 2003 freeze, http://www.genome.ucsc.edu).
Alternative splicing analysis. Alternative splicing analysis was
carried out on 1 ll of cDNA prepared from CD4
þ and CD4
  cell
populations from four individuals (two cases and two controls) as
described below. Both alleles of the rs1010546 SNP were PCR-
ampliﬁed under standard conditions with the use of an exonic primer
couple (amplifying a product spanning from exon 6 to exon 8; primer
sequences are available on request).
MS and control lymphocyte samples. We collected fresh blood
samples from 24 members of ﬁve extended MS families. Samples were
obtained from MS cases and healthy family members, of whom 13
were females and 11 were males. All donors gave their informed
consent, and the study was approved by ethical committees of
Helsinki University and Seina ¨joki Central Hospitals.
The lymphocytes were immediately harvested using Ficoll-Paque
density gradient centrifugation and further stratiﬁed to CD4
þ and
CD4
 cell populations by negative selection with CD4
þT cell isolation
kit (Miltenyi Biotec, Auburn, California, United States) using
autoMACS instrument (Miltenyi Biotec). The total cellular RNA was
extracted using Trizol reagent followed by DNAse I treatment and
additional puriﬁcation with RNeasy Mini Kit columns (Qiagen,
Valencia, California, United States) according to the manufacturers’
instruction. The quality of the RNA was assessed using the RNA 6000
Nano assay in the Bioanalyzer (Agilent, Foster City, California, United
States) monitoring for ribosomal S28/S18 RNA ratio (acceptable 1.5–
2.5), signs of degradation, and DNA contamination. The concen-
tration and the A260/A280 ratio of the samples were measured using
a spectrophotometer, the acceptable ratio being 1.8–2.2. We obtained
adequate amount of good-quality total RNA from eight MS cases and
nine controls for the CD4
 cell pool, and for six cases and six controls
for the CD4
þ T lymphocytes. All individuals, from whom we had
obtained blood mononuclear cell samples and high-quality RNA, had
at least one copy of the MS risk haplotype (C-A), thus we were able to
compare the relative expression level of PRKCA in individuals with
two risk haplotypes to those heterozygous for the risk haplotype.
Quantitative RT-PCR. Random hexamers and the TaqMan Gold
RT-PCR kit (Applied Biosystems) were used to perform ﬁrst strand
cDNA synthesis starting from 1 lg of total RNA, according to
manufacturer’s instructions. Real-time PCRs for the quantitation of
the PRKCA mRNA were carried out using the SYBR-Green assay
(Applied Biosystems). Exonic primer couples for PRKCA, and for the
three genes used in the normalization step (glyceraldehyde-3-
phosphate dehydrogenase [GADPH], hydroxymethylbilane synthase
[HMBS], and b-actin [ACTB]) were purchased from Proligo (Paris,
France), and their sequences are available on request. All reactions
were performed in triplicate using the ABI Prism 7900 HT Sequence
Detection System, and data were analyzed with the Sequence
Detector version 2.0 software (Applied Biosystems).
Bioinformatic analysis of the genotype and expression data of
CEPH individuals. We obtained the expression and genotype data of
CEPH individuals from two recent publications by Monks and
collaborators [28] and Hinds and co-workers [29] available in the
public databases. Eleven CEPH individuals of European ancestry
(NA07019, NA07348, NA07349, NA10831, NA10844, NA10845,
NA10853, NA10854, NA10857, NA10860, and NA10861) were used
in both studies and thus had both expression and genotype data
available. Genotypes for SNPs rs2078153 and rs7215972 for all the 24
CEPH individuals of European ancestry were obtained from http://
genome.perlegen.com and used to estimate two-SNP haplotypes
[48,49]. SNP rs7215972, which is located between SNPs rs3889477 and
rs3890137 (block 7 in Canadian samples, see Figure 2), was utilized
instead of rs3890137, since neither of the SNPs in that block were
genotyped by Hinds and co-workers [29]. All estimated haplotypes
had a probability of 1.0. The expression of PRKCA (ID: 10012668758)
had been measured in lymphoblast cell lines of 167 CEPH individuals
[28], and the data was downloaded from http://www.ncbi.nlm.nih.gov/
geo (GSE1726 record). The relative expression level of each gene was
given as log10 (expression ratio), comparing individual samples to a
common pool created from equal portions of RNA from founders
within the 15 CEPH families. The average expression level of the
PRKCA gene was calculated for individuals with two, one, or no
copies of the putative disease haplotype (rs2078153–rs3890137: C-A).
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